Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Anti-tumor Effects of Idarubicin Hydrochloride in Desmoid Tumors.
Anticancer Res
December 2024
Drug Discovery Platform Research Center, Therapeutics and Biotechnology Division, Korea Research Institute of Chemical Technology (KRICT), Daejeon, Republic of Korea;
Background/aim: Desmoid tumors (DTs), also referred to as aggressive fibromatosis, originate from connective tissues and typically manifest with a propensity for local invasion. Despite extensive research efforts aimed at exploring novel anti-tumor agents for DTs, the development of effective clinical management strategies remains an ongoing challenge due to the limited success of current treatments, which frequently lead to inconsistent outcomes and a high recurrence rate of DTs. To overcome these limitations, we focused our research aim on a drug repositioning approach to identify existing medications that could be effective against DTs.
View Article and Find Full Text PDFActive surveillance in patients with extra-abdominal desmoid-type fibromatosis: a pooled analysis of three prospective observational studies.
Clin Cancer Res
December 2024
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Purpose: Three prospective observational studies (Italy, the Netherlands, France) on active surveillance (AS) in patients with extra-abdominal desmoid-type fibromatosis (DTF) support AS as a frontline approach. Identifying prognostic factors for the failure of AS will help determine the strategy. The aim of this study was to investigate the prognostic impact of clinical and molecular variables in a larger series.
View Article and Find Full Text PDFGenomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors.
Clin Cancer Res
January 2025
Department of Surgery, McGill University, Montreal, Quebec, Canada.
Purpose: Desmoid tumors are bland fibroblastic tumors that do not metastasize but have a high rate of local recurrence. Previously published studies proposed two different transcriptomic signatures to predict relapse. Molecular heterogeneity has been well established in high-grade sarcomas, but little is known about molecular variability within locally aggressive tumors such as desmoids.
View Article and Find Full Text PDFCirculating Tumor DNA in Patients with Desmoid Fibromatosis during Active Surveillance.
Ann Surg Oncol
December 2024
Sarcoma Service, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Article Synopsis
- Sporadic desmoid fibromatosis (DF) is a rare and aggressive tumor linked to mutations in the CTNNB1 gene, with standard treatment being active surveillance, although 30% may require additional therapy due to unpredictable disease progression.
- In a study involving 56 patients, the researchers analyzed both tumor biopsies and plasma samples to assess the presence and quantity of circulating tumor DNA (ctDNA) correlating to CTNNB1 mutations, finding varying detection rates for different mutations.
- The findings suggest a potential role for ctDNA as a diagnostic tool to monitor disease progression, warranting further clinical trials to determine its effectiveness as a predictive biomarker in managing sporadic DF.
Anti-proliferative impact of resveratrol on gingival fibroblasts from juvenile hyaline fibromatosis.
Clin Oral Investig
July 2024
Forsyth Institute, Cambridge, MA, USA.
Aim: Resveratrol is a natural polyphenolic compound with biological activities such as anti-inflammation and antioxidation. Its anti-fibrotic effect has been experimentally demonstrated in the pancreas and liver. This study aims to determine the anti-proliferative effect of resveratrol on fibroblasts obtained from hyperplastic gingival tissues from a patient diagnosed with Juvenile Hyaline Fibromatosis (JHF).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!